In hormone-receptor-positive (HR+) BC, ctDNA frequently detects ESR1 mutations (e.g., Y537S) [82], which confer endocrine resistance, as well as PIK3CA mutations [83,84], which predict resistance to CDK4/6 inhibitors and guide the use of alpelisib. This evidence concerns the gene NR4A1 and breast cancer.